Abstract 580P
Background
ARCHER 1050 has demonstrated a potential efficacy of first-line dacomitinib for Chinese non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) 21L858R mutation but with limited data. This study aims to provide more evidence for the application of first-line dacomitinib treating advanced NSCLC patients with EGFR 21L858R mutation in China and explore influential factors of clinical outcomes.
Methods
A longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data was conducted. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included duration of treatment (DOT), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety.
Results
A total of 155 EGFR 21L858R mutant patients treated with first-line dacomitinib were included into this study. The median follow-up time for these patients was 20.4 months. Among 134 patients with target lesions, the ORR was 70.9% and the DCR was 96.3%. The median PFS was 16.3 months (95%CI, 13.7-18.9). Univariate Cox regression analysis suggested that baseline brain metastasis (BM) status (with vs. without BM: HR, 1.171; 95%CI, 0.730-1.878; p = 0.513) and initial dose (45mg vs. 30mg: HR, 0.980; 95%CI, 0.564-1.701; p = 0.943) didn’t have significant impact on the median PFS. The median DOT was 21.0 months (95%CI, 17.5-24.6) and the median OS was not reached. The most common grade 3-4 adverse events were rash (10.4%), diarrhea (9.1%), stomatitis (7.1%) and paronychia (4.5%).
Conclusions
First-line dacomitinib treatment demonstrated promising efficacy and tolerable adverse events among Chinese NSCLC patients with EGFR 21L858R mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract